This study is not yet accepting patients
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Dates
- study startedcompletion around
- Principal Investigator
- by Adil Daud
Description
Summary
Official Title
Keywords
Eligibility
Lead Scientist at UCSF
- Adil Daud
Professor, Medicine, School of Medicine. Authored (or co-authored) 210 research publications
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- TuHURA Biosciences, Inc.
- ID
- NCT06947928
- Phase
- Phase 2/3 research study
- Study Type
- Interventional
- Participants
- Expecting 118 study participants
- Last Updated